Sars-Cov-2 B.1.1.529 (Omicron) variant outbreak: case series presentations and response to treatment at the Islamic University in Uganda health facility

Keywords: Sars-Cov-2 B.1.1.529, Omicron, Presentations, Characteristics, Response to Treatment, steaming, herbal treatment, home-based care, Uganda

Abstract

The object of research: The study, investigated the clinical presentations of patients who tested Positive for Covid-19 (Omicron Variant), their response to treatment, and the levels of transmissibility of the infection.

Investigated problem: As the globe, continent, and nation are struggling with the emergency of the new COVID-19 omicron Virant outbreak there’s not much information known about the behavior of this new threat to enable clinicians, and public health specialists, and policymakers to curb the problem.

The main scientific results: The study found that headache, cough, fevers and, general body weakness was the commonest presenting complaints, 3 of the cases reported difficulties in breathing. None of the cases required admission. There was no difference in the severity of the illness and the response to treatment between the vaccinated and the non-vaccinated cases. Cases that did steaming as an adjuvant/supplementary treatment reported a shorter duration of symptomatic relief than those that did not.

The area of practical use of the research results: The findings will act as a practical guide to clinicians, public health specialists, and policymakers in the management of the COVID-19 Omicron Variant.

Innovative technological product: The use of steaming as an adjuvant to symptomatic relief management of respiratory tract infections.

Scope of the innovative technological product: Omicron Variant produces a less severe illness than earlier variants of COVID-19. The study also reveals that vaccination alone was not effective in the prevention of contraction of the Omicron Variant and other newer variants. However, vaccination may have been advantageous in protecting the cases from progressing to severe disease. Thus, other IPCs measures must be maintained and booster doses of COVID-19 vaccinations should be encouraged. Large-scale on the effectiveness of steaming and other locally made remedies for symptomatic management of respiratory tract infections should be done.

Downloads

Download data is not yet available.

Author Biography

Naziru Rashid, Islamic University in Uganda

Medical Superintendent

IUIU Health Center

References

SARS-CoV-2 Variant Classifications and Definitions (2021). Available at: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html Last accessed: 04.04.2022

Arora, S., Grover, V., Saluja, P., Algarni, Y. A., Saquib, S. A., Asif, S. M. et. al. (2022). Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms, 10 (2), 451. doi: http://doi.org/10.3390/microorganisms10020451

Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., Gray, G. (2022). Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. New England Journal of Medicine, 386 (5), 494–496. doi: http://doi.org/10.1056/nejmc2119270

Gu, H., Krishnan, P., Ng, D. Y. M., Chang, L. D., Liu, G. Y. Z., Cheng, S. S. M. et. al. (2022). Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021. Emerging Infectious Diseases, 28 (2), 460–462. doi: http://doi.org/10.3201/eid2802.212422

Rashid, N., Swaibu, Z. (2021). Knowledge, Attitude, and Perception on Hepatitis B Vaccination Among Non-health Workers Attending Selected Health Facilities in Mbale City, Uganda. World Journal of Public Health, 6 (4), 139–147.

He, X., Hong, W., Pan, X., Lu, G., Wei, X. (2021). SARS‐CoV‐2 Omicron variant: Characteristics and prevention. MedComm, 2 (4), 838–845. doi: http://doi.org/10.1002/mco2.110

Rashid, N., Nazziwa, A., Kantono, R., Kasujja, H., Zziwa, S. (2021). Assessing Knowledge and Practices of the Community towards Corona Virus Disease 2019 in Mbale Municipality, Uganda: Across Section Study. East African Health Research Journal, 5 (1), 20–25. doi: http://doi.org/10.24248/eahrj.v5i1.647

Jansen, L., Tegomoh, B., Lange, K., Showalter, K., Figliomeni, J., Abdalhamid, B. et. al. (2021). Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster – Nebraska, November–December 2021. MMWR. Morbidity and Mortality Weekly Report, 70 (5152), 1782–1784. doi: http://doi.org/10.15585/mmwr.mm705152e3

Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., Tartof, S. Y. (2022). Title: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. doi: http://doi.org/10.1101/2022.01.11.22269045

What we know about the Omicron variant (2022). UNICEF. Available at: https://www.unicef.org/coronavirus/what-we-know-about-omicron-variant#symptoms Last accessed: 04.04.2022

Torjesen, I. (2021). Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ, n2943. doi: http://doi.org/10.1136/bmj.n2943


👁 83
⬇ 23
Published
2022-02-28
How to Cite
Rashid, N. (2022). Sars-Cov-2 B.1.1.529 (Omicron) variant outbreak: case series presentations and response to treatment at the Islamic University in Uganda health facility. ScienceRise, (1), 36-40. https://doi.org/10.21303/2313-8416.2022.002369
Section
Innovative technologies in healthcare